← Back to Search

SGLT2 Inhibitor

Zibotentan + Dapagliflozin for Liver Cirrhosis (ZEAL Trial)

Phase 2
Recruiting
Research Sponsored by AstraZeneca
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at week 6 and week 16

Summary

This trial is testing a combination of two drugs, zibotentan and dapagliflozin, and also dapagliflozin alone. It targets people with liver disease (cirrhosis) that causes high blood pressure in the liver's veins. The treatment aims to lower this high blood pressure and improve liver health. Dapagliflozin is a medication that has been shown to reduce cardiovascular death and heart failure.

Who is the study for?
The ZEAL Study is for adults with liver cirrhosis and portal hypertension who haven't used SGLT2 inhibitors or endothelin receptor antagonists recently. They should have stable liver function, no recent severe kidney injury, variceal hemorrhage, or significant heart failure. Women must be non-pregnant, not breastfeeding, and either post-menopausal or surgically sterile.
What is being tested?
This study tests the safety and effectiveness of combining zibotentan with dapagliflozin versus placebo in treating liver cirrhosis with portal hypertension. It's a double-blind trial meaning neither participants nor researchers know who gets the real treatment versus a placebo.
What are the potential side effects?
Potential side effects may include typical drug reactions like nausea, headaches, possible kidney function changes due to dapagliflozin (a diabetes medication), and risks associated with zibotentan which could affect blood pressure since it targets blood vessel constriction.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at week 6 and week 16
This trial's timeline: 3 weeks for screening, Varies for treatment, and at week 6 and week 16 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Part A: Absolute change in HVPG from baseline to Week 6.
Part B: Absolute change in HVPG from baseline to Week 6.
Secondary study objectives
Part A: Change in systolic and diastolic blood pressure from baseline to Week 6.
Part A: Change in total body water, extracellular water and intracellular water volumes from baseline to Week 6. Change in total body fat mass from baseline to Week 6.
Part A: Evaluation of change in body weight (kg) over time course of study. Percentage and absolute change from baseline in body weight at Week 6.
+9 more

Trial Design

7Treatment groups
Experimental Treatment
Group I: Part B: Treatment Group 5Experimental Treatment1 Intervention
Participants will receive once daily dose of zibotentan capsule + dapagliflozin tablet for 16 weeks.
Group II: Part B: Treatment Group 4Experimental Treatment1 Intervention
Participants will receive once daily dose of zibotentan capsule + dapagliflozin tablet for 16 weeks.
Group III: Part B: Treatment Group 3Experimental Treatment1 Intervention
Participants will receive once daily dose of zibotentan capsule + dapagliflozin tablet for 16 weeks.
Group IV: Part B: Treatment Group 2Experimental Treatment1 Intervention
Participants will receive once daily dose of placebo matching zibotentan capsule + dapagliflozin tablet for 16 weeks.
Group V: Part B: Treatment Group 1Experimental Treatment1 Intervention
Participants will receive once daily dose of placebo matching zibotentan capsule + placebo matching dapagliflozin tablet for 16 weeks.
Group VI: Part A: Treatment Group 2Experimental Treatment1 Intervention
Participants will receive once daily dose of zibotentan capsule + dapagliflozin tablet for 6 weeks.
Group VII: Part A: Treatment Group 1Experimental Treatment1 Intervention
Participants will receive once daily dose of placebo matching zibotentan capsule + placebo matching dapagliflozin tablet for 6 weeks.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Endothelin receptor antagonists, such as zibotentan, block the effects of endothelin-1, a molecule that causes blood vessels to constrict, thereby reducing intrahepatic resistance and portal hypertension in liver cirrhosis. SGLT2 inhibitors like dapagliflozin lower blood glucose levels and may also have anti-inflammatory and antifibrotic effects. These treatments are important for liver cirrhosis patients as they address key pathological processes, potentially improving liver function and reducing complications related to portal hypertension.
Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in adults with cirrhosis.Novel treatment options for portal hypertension.[Hepatotoxicity in patients treated with endothelin receptor antagonists: systematic review and meta-analysis of randomized clinical trials].

Find a Location

Who is running the clinical trial?

AstraZenecaLead Sponsor
4,375 Previous Clinical Trials
288,738,548 Total Patients Enrolled
2 Trials studying Liver Cirrhosis
98 Patients Enrolled for Liver Cirrhosis

Media Library

Dapagliflozin (SGLT2 Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT05516498 — Phase 2
Liver Cirrhosis Research Study Groups: Part B: Treatment Group 4, Part A: Treatment Group 2, Part B: Treatment Group 5, Part B: Treatment Group 1, Part B: Treatment Group 2, Part B: Treatment Group 3, Part A: Treatment Group 1
Liver Cirrhosis Clinical Trial 2023: Dapagliflozin Highlights & Side Effects. Trial Name: NCT05516498 — Phase 2
Dapagliflozin (SGLT2 Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05516498 — Phase 2
Liver Cirrhosis Patient Testimony for trial: Trial Name: NCT05516498 — Phase 2
~22 spots leftby Jan 2025